Advertisement

Regionale Chemotherapie bei Kopf-Hals-Tumoren

  • Adorján F. Kovács

Zusammenfassung

Die überwiegende Mehrheit der Kopf-Hals-Tumoren sind Plattenepithelkarzinome; daher werden andere Histologien in diesem Kapitel nicht besprochen. Nach Angaben der Deutschen Krebsgesellschaft [1] ist der alleinige Einsatz der (systemischen) Chemotherapie bei Kopf-Hals-Tumoren »bei Krankheitsrückfällen (Rezidiv) oder metastasierten, also gestreuten Tumoren« nur für den palliativen Gebrauch bestimmt. Für Kopf-Hals-Tumoren, die nicht resektabel sind, »wird die Chemotherapie in der Regel mit einer Bestrahlung kombiniert (Radiochemotherapie)«, entweder parallel oder sequentiell. Heute ist der Vorteil der parallelen Radiochemotherapie einer sequentiellen Therapie gegenüber bestätigt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    German Cancer Society, Head-Neck-Tumors, Treatment 2009 [Deutsche Krebsgesellschaft, Kopf-Hals-Tumoren, Therapie 2009]. (www.krebsgesellschaft.de/pat_ka_kopf_hals_tumor_therapie,108203.html).
  2. 2.
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta- analysis of chemotherapy on head and neck Cancer. Lancet. 2000;355:949–55.Google Scholar
  3. 3.
    Taylor 4th SG, Murthy AK, Vannetzel JM, Colin P, Dray M, Caldarelli DD, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol. 1994;12:385–95.Google Scholar
  4. 4.
    Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent post-operative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck. 2005;27:843–50.CrossRefGoogle Scholar
  5. 5.
    Robbins KT. The evolving role of combined modality therapy in head and neck Cancer. Arch Otolaryngol Head Neck Surg. 2000;126:265–9.Google Scholar
  6. 6.
    Domenge C, Hill C, Lefebvre JL, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d‹Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer. 2000;83:1594–8.CrossRefGoogle Scholar
  7. 7.
    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995;71:83–91.PubMedCrossRefGoogle Scholar
  8. 8.
    Pignon JP, le Maître A, Maillard E, Bourhis J, Collaborative Group MACH-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92:4–14.Google Scholar
  9. 9.
    Stell PM, Rawson NS. Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990;61:779–87.CrossRefGoogle Scholar
  10. 10.
    Volling P, Schröder M, Eckel H, Ebeling O, Stennert E. Primäre Chemotherapie bei Mundhöhlen- und Tonsillenkarzinomen. Ergebnisse einer prospektiv randomisierten Studie [Results of a prospective randomized trial with induction chemotherapy for cancer of the oral cavity and tonsils]. HNO. 1999;47:899–906.PubMedCrossRefGoogle Scholar
  11. 11.
    Laccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H. Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer. 2001;92:1504–11.CrossRefGoogle Scholar
  12. 12.
    Kovács AF, Grüterich G, Wagner M. Long-term complete remission of oral cancer after antineoplastic chemotherapy as single treatment modality: role of local chemotherapy. J Chemother. 2002;14:95–101.PubMedGoogle Scholar
  13. 13.
    Weaver A, Fleming S, Vandenberg H, Drelichman A, Jacobs J, Kinzie J, et al. Cis-platinum and 5-fluorouracil as initial therapy in advanced epidermoid cancers of the head and neck. Head Neck Surg. 1982;4:370–3.CrossRefGoogle Scholar
  14. 14.
    Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993;85:95–111.PubMedCrossRefGoogle Scholar
  15. 15.
    De Andres L, Brunet J, Lopez-Pousa A, Burgues J, Vega M, Tabernero JM, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 1995;13:1493–500.Google Scholar
  16. 16.
    Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–63.Google Scholar
  17. 17.
    Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994;86:265–72.CrossRefGoogle Scholar
  18. 18.
    Thyss A, Schneider M, Santini J, Caldani C, Vallicioni J, Chauvel P, et al. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer. 1986;54:755–60.CrossRefGoogle Scholar
  19. 19.
    Wang HM, Wang CH, Chen JS, Chang HK, Kiu MC, Liaw CC, et al. Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc. 1995;94:87–94.PubMedGoogle Scholar
  20. 20.
    Clark JR, Busse PM, Norris Jr CM, Andersen JW, Dreyfuss AI, Rossi RM, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol. 1997;15:3100–10.Google Scholar
  21. 21.
    El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996;14:838– 47.Google Scholar
  22. 22.
    Posner MR, Colevas AD, Tishler RB. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck. Semin Oncol. 2000;27 Suppl 8:13–24.PubMedGoogle Scholar
  23. 23.
    Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.Google Scholar
  24. 24.
    Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B, et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98–02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys. 2004;58:161–6.CrossRefGoogle Scholar
  25. 25.
    Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.CrossRefGoogle Scholar
  26. 26.
    Bourhis J, Lapeyre M, Tortochaux J, Rives M, Aghili M, Bourdin S, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol. 2006;24:2873–8.CrossRefGoogle Scholar
  27. 27.
    Urba SG, Forastiere AA, Wolf GT, Esclamado RM, McLaughlin PW, Thornton AF. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. J Clin Oncol. 1994;12:946–53.Google Scholar
  28. 28.
    Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.CrossRefGoogle Scholar
  29. 29.
    Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20:921–7.CrossRefGoogle Scholar
  30. 30.
    Ghi MG, Paccagnella A, D'Amanzo P, Mione CA, Fasan S, Paro S, et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys. 2004;59:481–7.CrossRefGoogle Scholar
  31. 31.
    Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.CrossRefGoogle Scholar
  32. 32.
    Kovács AF, Eberlein K, Hülsmann T. Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg. 2009;13:87–93.CrossRefGoogle Scholar
  33. 33.
    Baghi M, Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006;26:585–90.Google Scholar
  34. 34.
    Rapidis AD, Trichas M, Stavrinidis E, Roupakia A, Ioannidou G, Kritselis G, et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol. 2006; 42:675–84.CrossRefGoogle Scholar
  35. 35.
    Posner M, Vermorken JB. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008;35:221–8.CrossRefGoogle Scholar
  36. 36.
    Vermorken JB, Mesia R, Rivera F, Remenár É, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359:1116–27.CrossRefGoogle Scholar
  37. 37.
    Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer chemotherapy with methyl bis amine hydrochloride: a preliminary report. Ann Surg. 1950;132:811–32.CrossRefGoogle Scholar
  38. 38.
    Sullivan RD, Jones R, Schnabel TG, Shorey J. The treatment of human cancer with intraarterial nitrogen mustard utilizing a simplified catheter technique. Cancer. 1953; 6:121–4.Google Scholar
  39. 39.
    Kovács AF. Mundhöhlen- und Oropharynxkarzinome: neue Mittel und Wege der Therapie. Norderstedt: Books on demand; 2003 [Neuedition: Regionale Chemotherapie bei Kopf-Hals-Tumoren. Integration in multimodale Therapien. Berlin: Logos; 2012].Google Scholar
  40. 40.
    Eckardt A, Kelber A. Palliative, intraarterial chemotherapy for advanced head and neck cancer using an implantable port system. J Oral Maxillofac Surg. 1994;52:1243–6.CrossRefGoogle Scholar
  41. 41.
    Mees K, Lauterjung L, Kastenbauer E, Riederer A. Unsere Katheterführung zur intraarteriellen Chemotherapie bei Kopf- und Hals-Karzinomen [Personal catheter technic for intra-arterial chemotherapy in cancers of the head and neck]. Laryngol Rhinol Otol (Stuttg). 1987;66:460–4.Google Scholar
  42. 42.
    Bitter K. Erste Ergebnisse der zytostatischen Behandlung von Plattenepithelkarzinomen der Mundhöhle mit einer Kombination von Methotrexat und Bleomycin [Initial results of cytostatic therapy of squamous cell carcinoma of the oral cavity using a combination of methotrexate and bleomycin]. Dtsch Zahn Mund Kieferheilkd. 1973; 60:81–93.Google Scholar
  43. 43.
    Bitter K. Pharmacokinetic behaviour of bleomycin-cobalt- 57 with special regard to intraarterial perfusion of the maxillo-facial region. J Maxillofac Surg. 1976;4:226–31.CrossRefGoogle Scholar
  44. 44.
    Eckardt A, editor. Intra-arterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn-Presse Verlag; 1999.Google Scholar
  45. 45.
    Harker GJS, Stephens FO. Comparison of intra-arterial versus intravenous 5-fluorouracil in sheep bearing epidermal squamous carcinoma. Eur J Cancer. 1992;28: 1437– 41.CrossRefGoogle Scholar
  46. 46.
    Harker GJS. Intra-arterial infusion chemotherapy in a sheep squamous cell carcinoma model. In: Eckardt A, editor. Intra-arterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn- Presse Verlag; 1999.Google Scholar
  47. 47.
    Eckman WW, Patlack CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm. 1974;2: 257–85.Google Scholar
  48. 48.
    Campbell TN, Howell SB, Pfeifle CE, Wung WE, Bookstein J. Clinical pharmacokinetics of intraarterial cisplatin in humans. J Clin Oncol. 1983;1:755–62.Google Scholar
  49. 49.
    Weiss M. Pharmacokinetic rationale for arterial drug infusion. In: Eckardt A, editor. Intraarterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn-Presse Verlag; 1999.Google Scholar
  50. 50.
    Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2:498–504.PubMedGoogle Scholar
  51. 51.
    Abe R, Akiyoshi T, Koba F, Tsuji H, Baba T. »Two-route chemotherapy « using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. Eur J Cancer Clin Oncol. 1988;24: 1671– 4.Google Scholar
  52. 52.
    Robbins KT, Storniolo AM, Kerber C, Seagren S, Berson A, Howell SB. Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck. 1992;14:364–71.Google Scholar
  53. 53.
    Robbins KT, Storniolo AM, Kerber C, Vicario D, Seagren S, Shea M, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994;12:2113–20.Google Scholar
  54. 54.
    Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, et al. Characterization of a human squamous carcinoma cell line resistant to cisdiamminedichloroplati num(II). Cancer Res. 1987;47:388–93.Google Scholar
  55. 55.
    Los G, Blommaert FA, Barton R, Heath DD, den Engelse L, Hanchett C, et al. Selective intra-arterial infusion of highdose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemother Pharmacol. 1995;37:150–4.CrossRefGoogle Scholar
  56. 56.
    Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. »Decadose « effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope. 1996;106:37–42.Google Scholar
  57. 57.
    Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984; 35:419–25.CrossRefGoogle Scholar
  58. 58.
    Goel R, Cleary SM, Horton C, Kirmani S, Abramson I, Kelly C, et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst. 1989;81:1552–60.CrossRefGoogle Scholar
  59. 59.
    Pfeifle CE, Howell SB, Felthouse RD, Woliver TB, Andrews PA, Markman M, et al. High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol. 1985;3:237–44.Google Scholar
  60. 60.
    Muldoon LL, Pagel MA, Kroll RA, Brummett RE, Doolittle ND, Zuhowski EG, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res. 2000;6:309–15.Google Scholar
  61. 61.
    Kerber CW, Wong WH, Howell SB, Hanchett K, Robbins KT. An organ-preserving selective arterial chemotherapy strategy for head and neck cancer. AJNR Am J Neuroradiol. 1998;19: 935–41.Google Scholar
  62. 62.
    Kato T, Sato K, Sasaki R, Kakinuma H, Moriyama M. Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients. Cancer Chemother Pharmacol. 1996;37:289–96.CrossRefGoogle Scholar
  63. 63.
    Araki T, Hihara T, Kachi K, Matsusako M, Ito M, Kohno K, et al. Newly developed transarterial chemoembolization material: CDDP-lipiodol suspension. Gastrointest Radiol. 1989;14:46–8.Google Scholar
  64. 64.
    Brassel F. Technical aspects of superselective chemotherapy in head and neck cancer. In: Eckardt A, editor. Intraarterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn-Presse Verlag; 1999.Google Scholar
  65. 65.
    Okamoto Y, Konno A, Togawa K, Kato T, Amano Y. Microcapsule chemoembolization for head and neck cancer. Arch Otorhinolaryngol. 1985;242:105–11.Google Scholar
  66. 66.
    Okamoto Y, Konno A, Togawa K, Kato T, Tamakawa Y, Amano Y. Arterial chemoembolization with cisplatin microcapsules. Br J Cancer. 1986;53:369–75.CrossRefGoogle Scholar
  67. 67.
    Gouyette A, Apchin A, Foka M, Richard JM. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol. 1986;22:257–63.CrossRefGoogle Scholar
  68. 68.
    Sileni VC, Fosser V, Maggian P, Padula E, Beltrame M, Nicolini M, et al. Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. Cancer Chemother Pharmacol. 1992;30:221–5.CrossRefGoogle Scholar
  69. 69.
    Jakowatz JG, Ginn GE, Snyder LM, Dieffenbach KW, Wile AG. Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer. 1991;67:2828–32.CrossRefGoogle Scholar
  70. 70.
    Tohnai I, Fuwa N, Hayashi Y, Kaneko R, Tomaru Y, Hibino Y, et al. New superselective intra-arterial infusion via superficial temporal artery for cancer of the tongue and tumour tissue platinum concentration after carboplatin (CBDCA) infusion. Oral Oncol. 1998;34:387–90.CrossRefGoogle Scholar
  71. 71.
    Yoshimura H, Mishima K, Nariai Y, Sugihara M, Yoshimura Y. Targetting intraarterial infusion chemotherapy for oral cancers using Seldinger technique. In: Varma AK, Roodenburg JLN, editors. Oral oncology, volume VII. New Delhi: Macmillan India; 2001.Google Scholar
  72. 72.
    Tegeder I, Bräutigam L, Seegel M, Al-Dam A, Turowski B, Geisslinger G, et al. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther. 2003;73:417– 26.CrossRefGoogle Scholar
  73. 73.
    Iida E, Okada M, Mita T, Furukawa M, Ito K, Matsunaga N. Superselective intra-arterial chemotherapy for advanced maxillary sinus cancer: an evaluation of arterial perfusion with computed tomographic arteriography and of tumor response. J Comput Assist Tomogr. 2008;32:397–402.PubMedCrossRefGoogle Scholar
  74. 74.
    Ishii A, Korogi Y, Nishimura R, Kawanaka K, Yamura M, Ikushima I, et al. Intraarterial infusion chemotherapy for head and neck cancers: evaluation of tumor perfusion with intraarterial CT during carotid arteriography. Radiat Med. 2004;22:254–9.Google Scholar
  75. 75.
    Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, et al. Magnetic drug targeting-biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target. 2003;11:139–49.CrossRefGoogle Scholar
  76. 76.
    Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H, Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 2007;27:2019–22.Google Scholar
  77. 77.
    Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomised trials. Int J Radiat Oncol Biol Phys. 1992;23:483–9.CrossRefGoogle Scholar
  78. 78.
    Forastiere AA, Baker SR, Wheeler R, Medvec BR. Intra-arterial cisplatin and FUDR in advanced malignancies confined to the head and neck. J Clin Oncol. 1987;5:1601–6.Google Scholar
  79. 79.
    Kovács AF. Relevance of positive margins in case of adjuvant therapy of oral cancer. Int J Oral Maxillofac Surg. 2004;33:447–53.CrossRefGoogle Scholar
  80. 80.
    Stephens FO. Intra-arterial chemotherapy in head and neck cancer. Historical perspectives – important developments, contributors and contributions. In: Eckardt A, editor. Intra-arterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn- Presse Verlag; 1999.Google Scholar
  81. 81.
    Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987;5:10–20.PubMedGoogle Scholar
  82. 82.
    Frei E, Clark JR, Fallon BG. Guidelines, regulations and clinical research. J Clin Oncol. 1986;4:1026–30.Google Scholar
  83. 83.
    Volling P, Schröder M. Vorläufige Ergebnisse einer prospektiv randomisierten Studie zur primären Chemotherapie bei Mundhöhlen- und Pharynxkarzinomen [Preliminary results of a prospective randomized study of primary chemotherapy in carcinoma of the oral cavity and pharynx]. HNO. 1995;43:58–64.PubMedGoogle Scholar
  84. 84.
    Baghi M, Mack MG, Hambek M, Bisdas S, Muerthel R, Wagenblast J, et al. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck. 2007;29:104–8.CrossRefGoogle Scholar
  85. 85.
    Kovács AF, Turowski B, Stefenelli U, Metzler D. Primary tumor volume as predicitive parameter for remission after intraarterial high-dose cisplatin in oral and oropharyngeal cancer: a mathematical model analysis. Chir Czaszkowo Szczęnkowo Twarzowa I Ortop Szczęnkowa Cranio Maxillofac Surg Orthodont. 2008;3:174–86.Google Scholar
  86. 86.
    Baker SR, Wheeler RH. Intraarterial chemotherapy for head and neck cancer: Part I. Theoretical considerations and drug delivery systems. Head Neck Surg. 1983;6:664– 82.CrossRefGoogle Scholar
  87. 87.
    Cruz Jr AB, McInnis WD, Aust JB. Triple drug intra-arterial infusion combined with x-ray therapy and surgery for head and neck cancer. Am J Surg. 1974;128:573–9.CrossRefGoogle Scholar
  88. 88.
    Armstrong AL, Meeker WR. Palliation of inoperable head and neck cancer: combined intra-arterial infusion chemotherapy and irradiation. South Med J. 1978; 71:1228–31.CrossRefGoogle Scholar
  89. 89.
    Curioni C, Quadu G. Clinical trial of intra-arterial polychemotherapy in the treatment of carcinoma of the oral cavity. J Maxillofac Surg. 1978;6:207–16.CrossRefGoogle Scholar
  90. 90.
    Szabó G, Kovács Á. Possibilities of enhancing the effectiveness of intra-arterial chemotherapy. Int J Oral Surg. 1980;9:33–44.PubMedCrossRefGoogle Scholar
  91. 91.
    Koch U, Straehler-Pohl HJ, Helpap B, Frommhold H. Intraarterielle Chemotherapie bei Karzinomen der oberen Speisewege (Erfahrungsbericht über 128 Patienten) [Intraarterial chemotherapy in carcinomas of the oral cavity, oro- and hypopharynx]. Laryngol Rhinol Otol (Stuttg). 1981;60:71–6.Google Scholar
  92. 92.
    Mika H. Die Remission ausgedehnter Karzinome der Mundhöhle und des Oropharynx unter intraarterieller Polychemotherapie mit Vincristin, Methotrexat, Bleomycin, Cisplatin (VMBP) [The remission of extensive cancers of the mouth and oropharynx with intra-arterial polychemotherapy with vincristine, methotrexate, bleomycin, cisplatin (VMBP)]. Laryngol Rhinol Otol (Stuttg). 1982;61:520–3.Google Scholar
  93. 93.
    Arcangeli G, Nervi C, Righini R, Creton G, Mirri MA, Guerra A. Combined radiation and drugs: the effect of intraarterial chemotherapy followed by radiotherapy in head and neck cancer. Radiother Oncol. 1983;1:101–7.CrossRefGoogle Scholar
  94. 94.
    Molinari R, Jortay A, Sancho-Garnier H, Brugere J, Demard M, Desaulty A, et al. A randomized EORTC trial comparing intra-arterial infusion with methotrexate vs bleomycin as initial therapy in carcinoma of the oral cavity. Eur J Cancer Clin Oncol. 1982;18:807–12.CrossRefGoogle Scholar
  95. 95.
    Galmarini FC, Yoel J, Nakasone J, Molina CM. Intraarterial association of cis-platinum and bleomycin in head and neck cancer. Auris Nasus Larynx. 1985;12 Suppl 2:S234–8.Google Scholar
  96. 96.
    Milazzo J, Mohit-Tabatabai MA, Hill GJ, Raina S, Swaminathan A, Cheung NK, et al. Preoperative intra-arterial infusion chemotherapy for advanced squamous cell carcinoma of the mouth and oropharynx. Cancer. 1985; 56:1014–7.CrossRefGoogle Scholar
  97. 97.
    Inuyama Y, Fujii M, Tanaka J, Takaoka T, Hosoda H, Kohno N, et al. Combination chemotherapy with cisplatin and peplomycin in squamous cell carcinoma of the head and neck. Auris Nasus Larynx. 1986;13:191–8.CrossRefGoogle Scholar
  98. 98.
    Mortimer JE, Taylor ME, Schulman S, Cummings C, Weymuller Jr E, Laramore G. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers. J Clin Oncol. 1988;6:969–75.Google Scholar
  99. 99.
    Cheung DK, Regan J, Savin M, Gibberman V, Woessner W. A pilot study of intraarterial chemotherapy with cisplatin in locally advanced head and neck cancers. Cancer. 1988;61:903–8.CrossRefGoogle Scholar
  100. 100.
    Lee YY, Dimery IW, Van Tassel P, De Pena C, Blacklock JB, Goepfert H. Superselective intra-arterial chemotherapy of advanced paranasal sinus tumors. Arch Otolaryngol Head Neck Surg. 1989;115:503–11.CrossRefGoogle Scholar
  101. 101.
    Claudio F, Cacace F, Comella G, Coucourde F, Claudio L, Bevilacqua AM, et al. Intraarterial chemotherapy through carotid transposition in advanced head and neck cancer. Cancer. 1990;65:1465–71.CrossRefGoogle Scholar
  102. 102.
    Frustaci S, Barzan L, Caruso G, Ghirardo R, Foladore S, Carbone A, et al. Induction intra-arterial cisplatin and bleomycin in head and neck cancer. Head Neck. 1991;13:291–7.CrossRefGoogle Scholar
  103. 103.
    Richard JM, Kramar A, Molinari R, Lefèbvre JL, Blanchet F, Jortay A, et al. Randomised EORTC head and neck cooperative group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer. 1991;27:821–7.Google Scholar
  104. 104.
    Vieitez JM, Bilbao JI, Hidalgo OF, Martin S, Manzano RG, Tangco E. Intra-arterial chemotherapy with carboplatin and 5-fluorouracil in epidermoid cancer of the oropharynx and oral cavity. Reg Cancer Treat. 1991;4:152–5.Google Scholar
  105. 105.
    Hirai T, Korogi Y, Hamatake S, Nishimura R, Baba Y, Takahashi M, et al. Stages III and IV squamous cell carcinoma of the mouth: three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Cardiovasc Intervent Radiol. 1999;22:201–5.CrossRefGoogle Scholar
  106. 106.
    Korogi Y, Hirai T, Nishimura R, Hamatake S, Sakamoto Y, Murakami R, et al. Superselective intraarterial infusion of cisplatin for squamous cell carcinoma of the mouth: preliminary clinical experience. Am J Roentgenol. 1995; 165: 1269–72.CrossRefGoogle Scholar
  107. 107.
    Scheel JV, Schilling V, Kastenbauer E, Knöbber D, Böhringer W. Cisplatin intraarteriell und sequentielle Bestrahlung. Langzeitergebnisse [Intra-arterial cisplatin and sequential radiotherapy. Long-term follow-up]. Laryngorhinootologie. 1996;75:38–42.PubMedCrossRefGoogle Scholar
  108. 108.
    Siegel RS, Bank WO, Maung CC, Harisiadis L, Wilson WR. Assessment of efficacy and tolerance of high-dose intraarterial cisplatin in advanced head and neck tumors. Proc Am Soc Clin Oncol (Abstract 1582); 1998.Google Scholar
  109. 109.
    Wilson WR, Siegel RS, Harisiadis LA, Davis DO, Nguyen HH, Bank WO. High-dose intraarterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001;127:809–12.Google Scholar
  110. 110.
    Kovács AF, Turowski B, Ghahremani TM, Loitz M. Intraarterial chemotherapy as neoadjuvant treatment of oral cancer. J Craniomaxillofac Surg. 1999;27:302–7.CrossRefGoogle Scholar
  111. 111.
    Szabó G, Kreidler J, Hollmann K, Kovács Á, Németh G, Németh Z, et al. Intra-arterial pre-operative cytostatic treatment versus preoperative irradiation: a prospective, randomized study of lingual and sublingual carcinomas. Cancer. 1999;86:1381–6.CrossRefGoogle Scholar
  112. 112.
    Benazzo M, Caracciolo G, Zappoli F, Bernardo G, Mira E. Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer. Eur Arch Otorhinolaryngol. 2000;257:279–82.CrossRefGoogle Scholar
  113. 113.
    Bertino G, Benazzo M, Gatti P, Bernardo G, Corbella F, Tinelli C, et al. Curative and organ-preserving treatment with intra-arterial carboplatin induction followed by surgery and/or radiotherapy for advanced head and neck cancer: single-center five-year results. BMC Cancer. 2007; 7:62.PubMedCrossRefGoogle Scholar
  114. 114.
    Kovács AF. Chemoembolization using cisplatin crystals as neoadjuvant treatment of oral cancer. Cancer Biother Radiopharm. 2005;20:267–79.CrossRefGoogle Scholar
  115. 115.
    Damascelli B, Patelli GL, Lanocita R, Di Tolla G, Frigerio LF, Marchianò A, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol. 2003;181:253–60.CrossRefGoogle Scholar
  116. 116.
    Damascelli B, Patelli G, Tichá V, Di Tolla G, Frigerio LF, Garbagnati F, et al. Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol. 2007;18:1395–403.CrossRefGoogle Scholar
  117. 117.
    Molinari R, Chiesa F, Cantù G, Costa L, Grandi C, Sala L. Prognostic factors in cancer of the oral cavity and anterior oropharynx treated with preliminary neoadjuvant intra-arterial chemotherapy followed by surgery. In: Eckardt A, editor. Intra-arterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn-Presse Verlag; 1999.Google Scholar
  118. 118.
    Frustaci S, Barzan L, Comoretto R, Tumolo S, Lo Re G, Monfardini S. Local neurotoxicity after intra-arterial cisplatin in head and neck cancer. Cancer Treat Rep. 1987; 71:257–9.Google Scholar
  119. 119.
    Andersson T, Andreasson L, Björklund A, Brismar J, Elner A, Eneroth CM, et al. Intraarterial chemotherapy of malignant head and neck tumours with superselective angiographic technique. Acta Otolaryngol Suppl. 1979; 360:167–70.Google Scholar
  120. 120.
    Kovács AF. Intraarterial chemotherapy and chemoembolization in head and neck cancer. Establishment as a neoadjuvant routine method. Cancer Ther. 2003;1:1–9.Google Scholar
  121. 121.
    Kovács AF. Intra-arterial induction high-dose chemotherapy with cisplatin for oral and oropharyngeal cancer: long-term results. Br J Cancer. 2004;90:1323–8.CrossRefGoogle Scholar
  122. 122.
    Kovács AF, Turowski B. Chemoembolization of oral and oropharyngeal cancer using a high-dose cisplatin crystal suspension and degradable starch microspheres. Oral Oncol. 2002;38:87–95.PubMedCrossRefGoogle Scholar
  123. 123.
    Kovács AF, Obitz P, Wagner M. Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin. Br J Cancer. 2002; 86:196–202.PubMedCrossRefGoogle Scholar
  124. 124.
    Kovács AF. Maximized combined modality treatment of an unselected population of oral and oropharyngeal cancer patients. Final results of a pilot study compared with a treatment-dependent prognosis index. J Craniomaxillofac Surg. 2006;34:74–84.PubMedCrossRefGoogle Scholar
  125. 125.
    Kovács AF, Schiemann M, Turowski B. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel – three year results of a pilot study. J Craniomaxillofac Surg. 2002;30:112–20.Google Scholar
  126. 126.
    Kovács AF, Mose S, Böttcher HD, Bitter K. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer. Strahlenther Onkol. 2005;181:26–34.PubMedCrossRefGoogle Scholar
  127. 127.
    Platz H, Fries R, Hudec M. Computer-aided individual prognoses of squamous cell carcinomas of the lips, oral cavity and oropharynx. Int J Oral Maxillofac Surg. 1992; 21:150–5.CrossRefGoogle Scholar
  128. 128.
    Kovács AF. Response to intraarterial induction chemotherapy: a prognostic parameter in oral and oropharyngeal cancer. Head Neck. 2006;28:678–88.CrossRefGoogle Scholar
  129. 129.
    Kovács AF, Eberlein K, Smolarz A, Weidauer S, Rohde S. Organerhaltende Therapie bei inoperablen Patienten mit primären Mundhöhlen- und Oropharynxkarzinomen. Möglichkeiten und Grenzen [Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations]. Mund Kiefer Gesichtschir. 2006;10:168–77.CrossRefGoogle Scholar
  130. 130.
    Kishi K, Matsunaka M, Sato M, Sonomura T, Sakurane M, Uede K. T1 and T2 lip cancer: a superselective method of facial arterial infusion therapy – preliminary experience. Radiology. 1999;213:173–9.Google Scholar
  131. 131.
    Nakasato T, Katoh K, Sone M, Ehara S, Tamakawa Y, Hoshi H, et al. Superselective continuous arterial infusion chemotherapy through the superficial temporal artery for oral cavity tumors. AJNR Am J Neuroradiol. 2000;21:1917–22.Google Scholar
  132. 132.
    Wu CF, Chen CM, Chen CH, Shieh TY, Sheen MC. Continuous intraarterial infusion chemotherapy for early lip cancer. Oral Oncol. 2007;43:825–30.CrossRefGoogle Scholar
  133. 133.
    Wu CF, Chen CM, Shen YS, Huang IY, Chen CH, Chen CY, et al. Effective eradication of oral verrucous carcinoma with continuous intraarterial infusion chemotherapy. Head Neck. 2008;30:611–7.CrossRefGoogle Scholar
  134. 134.
    Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T, Nakahara R, et al. Intra-arterial chemoradiotherapy for locally advanced oral cavity cancer: analysis of therapeutic results in 134 cases. Br J Cancer. 2008;98:1039–45.CrossRefGoogle Scholar
  135. 135.
    Tomura N, Kobayashi M, Hirano J, Watarai J, Okamoto Y, Togawa K, et al. Chemoembolization of head and neck cancer with carboplatine microcapsules. Acta Radiol. 1996;37:52–6.Google Scholar
  136. 136.
    Tomura N, Kato K, Hirano H, Hirano Y, Watarai J. Chemoembolization of maxillary tumors via the superficial temporal artery using a coaxial catheter system. Radiat Med. 1998;16:157–60.Google Scholar
  137. 137.
    Li H, Wang C, Wen Y, Wu H. Treatment of squamous cell carcinoma of the tongue using arterial embolism with cisplatin-loaded albumin microspheres: a microstructural and ultrastructural investigation. Chin J Dent Res. 1999;2:61–6.Google Scholar
  138. 138.
    Suvorova IuV, Tarazov PG, Korytova LI, Sokurenko VP, Khazova TV. Arterial chemoembolization in the combined treatment of malignant tumors of the tongue and maxilla: preliminary results. Vestn Rentgenol Radiol. 2002;2:23–8.Google Scholar
  139. 139.
    Li WZ, Ma ZB, Zhao T. Transcatheter arterial chemoembolization of oral squamous-cell carcinoma: a clinicopathological observation. Di Yi Jun Yi Da Xue Xue Bao. 2004; 24:614–8.Google Scholar
  140. 140.
    He H, Huang J, Ping F, Chen G, Zhang S, Dong Y. Anatomical and clinical study of lingual arterial chemoembolization for tongue carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:e1–5.PubMedGoogle Scholar
  141. 141.
    Sokurenko VP, Korytova LI, Tarazov PG, Suvorova IuV. Intra- arterial chemotherapy and chemoembolization in the combined treatment for locally advanced carcinoma of the head and neck. Vopr Onkol. 2008;54:625–30.PubMedGoogle Scholar
  142. 142.
    Konno A, Ishikawa K, Terada N, Numata T, Nagata H, Okamoto Y. Analysis of long-term results of our combination therapy for squamous cell cancer of the maxillary sinus. Acta Otolaryngol Suppl. 1998;537:57–66.PubMedGoogle Scholar
  143. 143.
    Song M, Chen FJ, Zeng ZY, Wu GH, Wei MW, Guo ZM, et al. Clinical value of inducing chemotherapy for patients with advanced tongue cancer. Ai Zheng. 2002;21:68–70.PubMedGoogle Scholar
  144. 144.
    He H, Ping F, Chen G, Zhang S. Chemoembolization of tongue carcinoma with ethylcellulose microcapsuled carboplatinum and its basic study. Artif Cells Blood Substit Immobil Biotechnol. 2008;36:114–22.PubMedCrossRefGoogle Scholar
  145. 145.
    Milburn GHW, Truter MR. The crystal structures of cisand trans-dichlorodiammineplatinum (II). Inorg Phys Theor J Chem Soc (A). 1966;11:1609–16.CrossRefGoogle Scholar
  146. 146.
    Medac, editor. Professional information Medac Cisplatin Medac [in German]. Hamburg: Medac; 2000.Google Scholar
  147. 147.
    McEvoy GK, editor. American hospital formulary service drug information 91. Bethesda: American Society of Hospital Pharmacists; 1991.Google Scholar
  148. 148.
    Greene RF, Chatterji DC, Hiranaka PK, Gallelli JF. Stability of cisplatin in aqueous solution. Am J Hosp Pharm. 1979;36:38–43.PubMedGoogle Scholar
  149. 149.
    Kristjansson F, Sternson LA, Lindenbaum S. An investigation on possible oligomer formation in pharmaceutical formulations of cisplatin. Int J Pharm. 1988;41:67–74.CrossRefGoogle Scholar
  150. 150.
    Bastian P, Kissel T, Bartkowski R. Maligne Lebererkrankungen: Arterielle Chemo- und Embolisationstherapie mit Hilfe von Trägersystemen. PZ Prisma. 1999;6:235–48.Google Scholar
  151. 151.
    Damascelli B, Cantù G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92:2592–602.PubMedCrossRefGoogle Scholar
  152. 152.
    van Es RJ, Nijsen JF, Dullens HF, Kicken M, van der Bilt A, Hennink W, et al. Tumour embolization of the Vx2 rabbit head and neck cancer model with Dextran hydrogel and Holmium-poly(L-lactic acid) microspheres: a radionuclide and histological pilot study. J Craniomaxillofac Surg. 2001;29:289–97.PubMedCrossRefGoogle Scholar
  153. 153.
    Szepesi T, Stadler B, Hohenberg G, Hollmann K, Kühböck J, Mailath G. Prognostische Faktoren bei der Behandlung inoperabler orofazialer Malignome mit simultaner Radio- und Chemotherapie [Prognostic factors in the treatment of inoperable orofacial tumors with simultaneous radiotherapy and intra-arterial chemotherapy]. Strahlentherapie. 1985;161: 299–307.PubMedGoogle Scholar
  154. 154.
    Scholz F, Scholz R, Schratter A, Hollmann K. Intraarterielle Chemotherapie bei Tumoren im maxillo-facialen Bereich. In: Vinzenz K, Waclawiczek HW, editors. Chirurgische Therapie von Kopf-Hals-Karzinomen. New York: Springer; 1992.Google Scholar
  155. 155.
    Imai S, Kajihara Y, Munemori O, Kamei T, Mori T, Handa T, et al. Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers. Eur J Radiol. 1995;21:94–9.CrossRefGoogle Scholar
  156. 156.
    Robbins KT, Kumar P, Regine WF, Wong FS, Weir 3rd AB, Flick P, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997;38:263–71.PubMedCrossRefGoogle Scholar
  157. 157.
    Oya R, Ikemura K. Targeted intra-arterial carboplatin infusion with concurrent radiotherapy and administration of tegafur for advanced squamous cell carcinoma of the oral cavity and oropharynx. In: Eckardt A, editor. Intraarterial chemotherapy in head and neck cancer – current results and future perspectives. Reinbek: Einhorn-Presse Verlag; 1999.Google Scholar
  158. 158.
    Fuwa N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, et al. A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. Cancer. 2000;89:2099–105.PubMedCrossRefGoogle Scholar
  159. 159.
    Robbins KT, Kumar P, Wong FS, Hartsell WF, Flick P, Palmer R, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000; 22:687–93.PubMedCrossRefGoogle Scholar
  160. 160.
    Regine WF, Valentino J, Arnold SM, Haydon RC, Sloan D, Kenady D, et al. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001;19:3333–9.PubMedGoogle Scholar
  161. 161.
    Balm AJ, Rasch CR, Schornagel JH, Hilgers FJ, Keus RB, Schultze-Kool L, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck. 2004; 26:485–93.PubMedCrossRefGoogle Scholar
  162. 162.
    Homma A, Furuta Y, Suzuki F, Oridate N, Hatakeyama H, Nahahashi T, et al. Rapid super-selective high-dose cisplatin infusion with concomitant radiotherapy for advanced head and neck cancer. Head Neck. 2005;27:65–71.PubMedCrossRefGoogle Scholar
  163. 163.
    Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, et al. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol. 2005;23:1447–54.PubMedCrossRefGoogle Scholar
  164. 164.
    Spring PM, Valentino J, Arnold SM, Sloan D, Kenady D, Kudrimoti M, et al. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma. Cancer. 2005; 104:1765–71.PubMedCrossRefGoogle Scholar
  165. 165.
    Robbins KT, Vicario D, Seagren S, Weisman R, Pellitteri P, Kerber C, et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994;168:419–22.PubMedCrossRefGoogle Scholar
  166. 166.
    Rasch CRN, Hauptmann M, Schornagel J, Wijers O, Buter J, Gregor T, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase III trial. Cancer. 2010;116:2159–65.PubMedCrossRefGoogle Scholar
  167. 167.
    Ackerstaff AH, Balm AJ, Rasch CR, de Boer JP, Wiggenraad R, Rietveld DH, et al. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck. 2009;31:77–84.PubMedCrossRefGoogle Scholar
  168. 168.
    Endo S, Suzuki S, Tsuji K, Niwa H, Noguchi Y, Yoshida K, et al. Intraarterial concomitant chemoradiation for tongue cancer: analysis of 20 patients. Nippon Jibiinkoka Gakkai Kaiho. 2005;108:689–93.PubMedCrossRefGoogle Scholar
  169. 169.
    Iguchi H, Kusuki M, Nakamura A, Nishiura H, Kanazawa A, Takayama M, et al. Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma. Acta Otolaryngol Suppl. 2004; 554:55–61.PubMedGoogle Scholar
  170. 170.
    Iguchi H, Kusuki M, Nakamura A, Kanazawa A, Hachiya K, Yamane H. Outcome of preoperative concurrent chemoradiotherapy and surgery for resectable lingual squamous cell carcinoma greater than 3 cm: the possibility of less extensive surgery. Oral Oncol. 2006;42:391–7.CrossRefGoogle Scholar
  171. 171.
    Ishii A, Korogi Y, Hirai T, Nishimura R, Murakami R, Ikushima I, et al. Intraarterial infusion chemotherapy and conformal radiotherapy for cancer of the mouth: prediction of the histological response to therapy with magnetic resonance imaging. Acta Radiol. 2007;48:900–6.CrossRefGoogle Scholar
  172. 172.
    Ito K, Shiba H, Fujiwara K, Kunimoto Y, Tanimoto S, Higami Y, et al. Superselective intraarterial chemotherapy using low dose CBDCA and Pirarubicin with concurrent radiotherapy for head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho. 2005;108:195–201.PubMedCrossRefGoogle Scholar
  173. 173.
    Yamashita Y, Goto M, Katsuki T. Chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for oral cancer. Gan To Kagaku Ryoho. 2002;29:905–9.Google Scholar
  174. 174.
    Yamashita Y, Shikimori M, Goto M. Clinical trial of chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer. Gan To Kagaku Ryoho. 2005;32:1267–71.Google Scholar
  175. 175.
    Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, et al. Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer. 2009;115:4705–14.PubMedCrossRefGoogle Scholar
  176. 176.
    Ikushima I, Korogi Y, Ishii A, Hirai T, Yamura M, Nishimura R, et al. Superselective intra-arterial infusion chemotherapy for stage III/IV squamous cell carcinomas of the oral cavity: midterm results. Eur J Radiol. 2008;66:7–12.PubMedCrossRefGoogle Scholar
  177. 177.
    Rohde S, Kovács AF, Turowski B, Yan B, Zanella F, Berkefeld J. Intra-arterial high-dose chemotherapy with cisplatin as part of a palliative treatment concept in oral cancer. AJNR Am J Neuroradiol. 2005;26:1804–9.PubMedGoogle Scholar
  178. 178.
    Donegan WL, Harris P. Regional chemotherapy with combined drugs in cancer of the head and neck. Cancer. 1976;38:1479–83.PubMedCrossRefGoogle Scholar
  179. 179.
    Eckardt A, Kelber A, Pytlik C. Palliative intra-arterial (i.a.) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III and IV) head and neck cancer using implantable port-systems. Eur J Surg Oncol. 1995;21:486–9.CrossRefGoogle Scholar
  180. 180.
    Huntington MC, DuPriest RW, Fletcher WS. Intra-arterial bleomycin therapy in inoperable squamous cell carcinomas. Cancer. 1973;31:153–8.CrossRefGoogle Scholar
  181. 181.
    Matras H, Bürkle K, Watzek G, Kühböck J, Pötzi P, Dimopoulos J. Concept of cytostatic therapy in advanced tumours of the head and neck. J Maxillofac Surg. 1979;7:150–4.CrossRefGoogle Scholar
  182. 182.
    Teymoortash A, Bien S, Dalchow C, Sesterhenn A, Lippert BM, Werner JA. Selective high- dose intra-arterial cisplatin as palliative treatment for incurable head and neck cancer. Onkologie. 2004;27:547–51.PubMedCrossRefGoogle Scholar
  183. 183.
    Yokoyama J. Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer. Gan To Kagaku Ryoho. 2002;29:169–75.PubMedGoogle Scholar
  184. 184.
    Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12:153–9.CrossRefGoogle Scholar
  185. 185.
    Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22:1071–7.PubMedCrossRefGoogle Scholar
  186. 186.
    Nagai H, Takamaru N, Ohe G, Uchida D, Tamatani T, Fujisawa K, et al. Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas. Gan To Kagaku Ryoho. 2011;38:777–81.PubMedGoogle Scholar
  187. 187.
    Watanabe I, Yamazaki Y, Satoh M, Yamane G, Saito T. An autopsy case of oral cancer healed by single treatment with bleomycin, with a case report of double cancer of squamous cell carcinoma and adenocarcinoma. Shikwa Gakuho 1975;75:1640–5.PubMedGoogle Scholar
  188. 188.
    Amagasa T, Shioda S, Iwaki H, Yokoo E, Sato T, Tachibana T, et al. Long-term prognosis of oral squamous cell carcinoma histologically judged to have been eliminated by the treatment with bleomycin alone. Gan No Rinsho 1985;31:231–5.Google Scholar
  189. 189.
    Singer R, Weidauer H, Edler L, Osswald H. Long-term results of advanced oral mucosal carcinoma with vincristine, methotrexate, bleomycin and nucleoside rescue. A report of over 242 cases. Dtsch Z Mund Kiefer Gesichtschir 1984;8:264–70.PubMedGoogle Scholar
  190. 190.
    Kovács AF, Döbert N, Engels K. The effect of intraarterial high-dose cisplatin on lymph nodes in oral and oropharyngeal cancer. Indian J Cancer. 2012;49:230–5.CrossRefGoogle Scholar
  191. 191.
    Yokoyama J, Ohba S, Ito S, Fujimaki M, Shimoji K, Kojima M, et al. Impact of lymphatic chemotherapy targeting metastatic lymph nodes in patients with tongue cancer (cT3N2bM0) using intra-arterial chemotherapy. Head Neck Oncol. 2012;4:64.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Adorján F. Kovács
    • 1
  1. 1.PrivatpraxisNauheimDeutschland

Personalised recommendations